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Numerous studies  have been made  to determine  the effectiveness  in  man of vaccines
containing influenza A virus (1).  Andrewes and Smith (2)  showed that the subcutaneous
administration  of formalized filtrates  of mouse  lungs  infected with  the virus caused  an
increase  in neutralizing  antibodies  in human  beings.  Francis  and Magill  (3, 4)  found
that active tissue culture virus given either subcutaneously or intradermally stimulated
the production  of neutralizing  antibodies  in  a group  of volunteers  selected because  of
their  low  level  of antibodies.  Stokes,  Chenoweth,  Waltz,  Gladen,  and Shaw  (5) and
Stokes, McGuinness,  Langnor, and Shaw  (6) vaccinated  large groups of human beings
intramuscularly with either active tissue culture or active mouse lung virus and followed
these and larger groups of unvaccinated persons through epidemics of respiratory disease
which they considered to be influenza  A  (1).  These authors found that the attack rate
for  "febrile  respiratory  disease"  was lower  in  vaccinated than in unvaccinated  groups.
Smith,  Andrewes,  and Stuart-Harris  (7) and Taylor  and Dreguss  (8) studied the anti-
body  response  in man  which followed  the  subcutaneous  injection  of formolized mouse
lung virus.  These authors also followed large groups of vaccinated  volunteers and un-
vaccinated control groups through acute respiratory  disease epidemics which they showed
to be influenza A.  They obtained no evidence that vaccination  had produced immunity
to the clinical disease.  There is as yet no conclusive  evidence that any one of the vari-
ous vaccines  which  have been  studied regularly  produces  active  immunity to influenza
A  in man.
It  has been shown previously  (9)  that a formalized  complex  vaccine con-
taining  both influenza  A  virus and  the X strain  (10)  of  canine  distemper
virus  was  very effective  in  immunizing  ferrets  against  influenza  A  virus.
A  single  subcutaneous  injection  of  this  vaccine  in  normal  ferrets  stimu-
lated  the production  of antibodies  in  a concentration  entirely  comparable
with  that  which  followed  actual  infection  by  influenza  A  virus.  It  was
also shown  (9)  that ferrets which had been given the complex vaccine were
solidly immune to infection by antigenically different  strains of influenza A
virus  for at least  3 months.  Preliminary  observations  on small  numbers
of  human  volunteers  who  received  the  complex  ferret  vaccine  were  also
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reported  (9).  It seemed  possible  that if  the  complex  vaccine  resulted  in
the  production  of  a  concentration  of  antibodies in  man  comparable  with
that observed  in  ferrets,  it might  prove  more effective  as a  prophylactic
agent  against  influenza  A  than  other  types  of  vaccines  thus far  studied.
Consequently,  an investigation  of the specific antigenicity of various single
and complex  influenza  A  vaccines  was  undertaken.  It  is the  purpose  of
this paper to report the results of quantitative serological studies on groups
of human volunteers who were given these vaccines.
Methods
VIRUSES.-
Influenza A  Virus.-The following  three  derivatives  of  the  PR8 strain  (11)  main-
tained in three distinct biological environments during the past 6 years in this laboratory
were  used.
PR8-f has been kept continuously  in ferrets,  having been carried through 91 consecu-
tive  passages  in  this  species.
PR8-m, after a number of passages in ferrets, was adapted to mice and since has been
carried through 332 mouse lung passages.
PR8-tc, after  70 mouse  lung  passages,  was  introduced  into  chick  embryo-Tyrode-
tissue culture (12) and has been carried through 533 continuous passages in this medium.
For the purposes of this investigation, PR8-f and PR8-m were each inoculated on the
chorio-allantoic  membranes  of  developing  chick  embryos  (13),  and both  were  carried
independently  through  9  consecutive  serial  passages.  9  to  10  day  old  embryos  were
used.  0.1 cc. of virus suspension was inoculated  onto the membrane  in an artificial air
sac.  The embryos were incubated  for an additional  4 days after inoculation.  The in-
fected embryos  and the chorio-allantoic  membranes were  then harvested,  pooled,  and
ground to a  10 per cent suspension  in 0.85  per  cent NaCI.  This suspension  was used
for passage.
The W.S.  strain (14)  was a mouse-adapted strain which had been maintained  subse-
quently  by serial  passage in ferrets.
Canine Distemper Virus.-Two derivatives  of the X strain  (9) of canine  distemper
virus, which  was encountered accidentally  in ferrets inoculated  with strain  188  (15)  of
influenza A virus,  were used.
X-f, ferret passage series.  This strain had been passed repeatedly in ferrets and was
known  to produce  typical  signs  of distemper  after  either  subcutaneous  or  intranasal
injection  (10).  Moreover,  it  had been  shown  to alter  markedly  the  usual  course  of
influenza  A  virus  infection  in ferrets  (10).
X-ch,  chick  embryo  passage  series.  For the purposes  of this study,  attempts were
made  to propagate  the X strain  in  developing  chick embryos.  Plummer  (16)  has re-
ported previously the successful passage of canine distemper virus on the chorio-allantoic
membrane.  After  a number  of unsuccessful  attempts,  it was found  that the X strain
could be maintained  in an active state for at least 5 passages on the membrane.  9 day
old white Leghorn  embryos  were  used.  0.1  cc.  of an unfiltered  10 per cent suspension
in  0.85  per  cent  NaCl  of  infected  membrane  was  dropped  onto  the  chorio-allantoic
membrane  in an  artificial air sac.  The  embryos  were  then incubated  an  additional  6
336F.  L.  HORSFALL,  JR.,  E.  H.  LENNETTE,  AND  E.  R.  RICKARD
days.  Ferrets  were inoculated  intranasally with suspensions  prepared from membranes
of the 1st, 4th, and 5th passages, and all developed typical signs of severe distemper 8 to
11  days after  inoculation.
The Y strain  (10)  of canine  distemper  virus was  obtained from  the spleen  of  an in-
fected  dog.  This strain was  also  capable  of producing  typical  signs of  distemper after
inoculation  in ferrets.  It  had been  shown  previously  (10),  however,  that the Y strain
in no  way changed  the  normal course  of  influenza  A  virus  infection  in  this  species.
PREPARATON  OP EXPERIMENTAL  VACCINES.-
Vaccine No.  1.  Tissue Culture.-Influenza virus  PR8-tc was introduced  into flasks
containing  5  cc.  of  minced  chick  embryo-Tyrode-tissue  culture  medium.  The  flasks
were incubated  for  48  hours at  37C.  The  liquid  contents were  then  centrifuged  for
30 minutes at 8000  R.P.M.  at 4C.  The undiluted supernate  was kept in a low tempera-
ture storage  cabinet  (17)  at  -76
0C.  and was  not thawed  until immediately  before  it
was  used  for  vaccination.  This  vaccine  corresponded  quite  closely  to  that  used by
Francis  and Magill  (4).
Vaccine No.  2.  Mouse  Lung.-Influenza virus  PR8-m was  inoculated  intranasally
into  a  large  number  of  lightly  anesthetized  mice.  The  infected  mouse  lungs  were
harvested aseptically  4 days later.  The lungs were  cultured individually  and stored in
the low temperature cabinet for 48 hours.  They were then thawed, and those that were
bacteriologically  sterile were  pooled and ground  to a  10 per  cent suspension  in 0.85 per
cent  NaC1.  This  suspension  was  centrifuged  for  30  minutes  at  8000  R.P.M.  at  4C.
Sufficient  formalin was  added to make a final  concentration  of formaldehyde  of  1: 5000.
The suspension  was then kept  at 40C. for  7 days,  after which  the excess  formaldehyde
was neutralized by the  addition of sufficient  ammonia  water  to make a final concentra-
tion  of  1: 8000  ammonia.  The inactivated vaccine  was stored  at  -76C.  and was not
thawed until immediately before use.  This vaccine corresponded rather closely to those
used by Smith, Andrewes, and Stuart-Harris  (7)  and by Taylor and Dreguss  (8).
Vaccine No. 3.  Ferret Lung and Spleen.-Influenza  virus W.S.  strain was inoculated
intranasally  in an  anesthetized  normal ferret.  3 days  later  the ferret  was killed,  and
the lung and spleen  were  removed aseptically.  Approximately  90  per cent of  the lung
showed typical consolidation.  Equal amounts  by  weight of  the  lung and spleen  were
ground to a 20 per cent suspension in 0.85  per cent  NaC1.  The suspension was  centri-
fuged for  20  minutes  at 2000  R.P.M.  The  supernate  was diluted  to  10  per  cent,  and
sufficient  formalin  was added  to give  a final concentration  of formaldehyde  of  1:4000.
This suspension  was stored at 4C. for  10 days, after which  the excess formaldehyde  was
neutralized  by  the addition  of  sufficient  ammonia water  to  make  a final  concentration
of 1:  8000 ammonia.  The inactivated vaccine was stored at - 76C. and was not  thawed
until immediately before  it was used.
Vaccine No.  4.  Complex Ferret Lung and Spleen.-A  normal  ferret  was  inoculated
intranasally  with a  mixture  containing  equal parts  of  a  10-2  dilution  of  influenza  virus
W.S.  strain  and  a  10- 1 dilution  of  canine  distemper  virus  X-f.  Following  a  typical
course of  both influenza  and distemper,  the ferret  was killed  11  days  after inoculation.
The lung and spleen were removed  aseptically,  and equal amounts  of these organs  were
ground to a 20  per cent  suspension  in 0.85 per  cent NaCl.  The suspension  was centri-
fuged  for 20  minutes  at  2000  R.P.M.  The  supernate  was  diluted to  10 per  cent,  and
sufficient  formalin was added  to make  a final concentration  of formaldehyde  of 1:4000.
This  suspension  was  stored at 4C. for  10  days after  which  the  excess  formaldehyde
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was  neutralized by the addition of sufficient ammonia water to make a final concentra-
tion of ammonia of 1: 8000.  The inactivated vaccine was stored at - 76°C. and was not
thawed until immediately  prior  to administration.
Vaccine No.  5.  Complex Ferret Lung and Spleen.-A  normal ferret  was  inoculated
intranasally with a mixture containing equal parts of  a 10-2 dilution of influenza virus
W.S.  strain  and a  1 0
- 1 dilution  of  dog  spleen containing  canine  distemper virus, Y
strain.  The ferret was  killed 11  days after inoculation,  and the lung and spleen were
removed  aseptically.  Equal amounts  of  these  organs  were  ground  to a  20 per  cent
suspension  in 0.85  per  cent NaCI.  The  remainder  of  the procedure  followed in  the
preparation  of  this  vaccine  was  identical in every  respect with that used for vaccine
No.  4.  The inactivated vaccine was  stored at  -76°C.  and was not thawed until just
before use.
Vaccine No.  6.  Chick Embryo.-The 9th  chick  embryo passage  of  influenza  virus
PR8-f was inoculated  onto  the membrane  of 9 day old chick  embryos.  The  embryos
were  incubated for  an additional  10  days and were  then harvested  aseptically.  The
heads  and  legs  were removed,  and a  20 per  cent  suspension  of the  embryos  and the
chorio-allantoic  membranes  was  made  in  0.85  per  cent  NaCl.  The  suspension  was
centrifuged for  10 minutes at 1500 R.P.M.  The'supernate was stored in the low tempera-
ture cabinet  and was not thawed until immediately before  use.
Vaccine No. 7.  Complex Chick Embryo.-The 9th chick embryo passage of  influenza
virus PR8-f diluted  10-2 and the 2nd chick embryo passage  of canine  distemper virus
X-ch  diluted  10-'  were  mixed  and  inoculated  onto  the  membrane  of  9 day  old  chick
embryos.  After an additional incubation of 10 days the infected embryos were harvested
aseptically.  The heads  and legs were removed.  The embryos and the  chorio-allantoic
membranes  were ground to a 10  per cent suspension  in 0.85 per cent NaCl.  Sufficient
formalin  was  added  to make  a final concentration  of  formaldehyde  of  1:4000.  This
suspension was stored at 4°C. for 5 days when the excess formaldehyde was  neutralized
by the addition of sufficient  ammonia water to make  a  final concentration  of ammonia
of  1:8000.  The inactivated  vaccine was  stored at  -76C.  and was not  thawed until
immediately  before use.
Vaccine No. 8.  Chick Embryo.-The  8th chick  embryo  passage  of  influenza  virus
PR8-m was inoculated onto the membrane of  12 day old chick embryos.  The embryos
were  incubated  for  an additional 4  days  and then  harvested  aseptically.  The  heads
and legs were removed.  A 10 per cent suspensionof the embryos and the chorio-allantoic
membranes  was made in 0.85  per cent  NaCl.  This suspension  was  centrifuged  for 10
minutes at  1500 R.P.M.  The supernate  was stored at - 760C. until immediately before
it was used.
Vaccine No. 9.  Complex Chick Embryo.-The 9th chick embryo passage  of influenza
virus PR8-m in a dilution of 10 - 2 and the 2nd chick embryo passage of canine distemper
virus X-ch diluted 10- 1were mixed and inoculated  onto the membranes of  10 to  12 day
old  chick  embryos.  After  6  days'  additional  incubation  the  embryos  were  harvested
aseptically.  The heads and legs were removed and the embryos and membranes ground
to  a 20 per cent suspension  in 0.85 per  cent  NaCl.  Sufficient formalin  was  added  to
make  a final concentration  of formaldehyde  of 1:4000.  This  suspension was stored at
4°C. for 3 days, after which the excess formaldehyde was neutralized by the addition of
sufficient  ammonia  water  to  make  a final concentration  of ammonia  of  1:8000.  The
suspension  was  then  centrifuged  for  10  minutes  at  1500  R.P.M.  The  supernate  was
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distributed in pyrex ampoules,  frozen rapidly  in a mixture of alcohol and solid CO2,  and
desiccated  in the frozen state by the method of Bauer and Pickels  (18).  The desiccated
vaccine was  stored at 4°C.  It was  rehydrated  15 days after drying by  the additionof
sterile distilled water and was used immediately.
Serum.-
Serum  was  obtained  from  each  volunteer  immediately  before  vaccination  and  at
various  intervals  thereafter.  In many  instances  weekly  serum  specimens were  taken
during the 1st month after vaccination.  In all cases serum was obtained between 2 and
3  weeks  following  vaccination.  Sera  were  stored  at  4°C.  In  almost  every  instance
prevaccination  and postvaccination sera from the same individual were run in the same
neutralization  test.
Neutralization Test.-
The  exact  technique used  in the neutralization  tests  has been described  previously
(19).  Serum was inactivated at 56°C. for 30 minutes, and serial fourfold dilutions were
made in 0.85  per cent  NaCI.  Equal  quantities  of the  various  serum dilutions  and a
constant  amount  of  the PR8 strain  of  influenza  A virus  were mixed.  In some  tests,
depending upon the titer of the serum,  10' 6 fifty per cent mortality doses of virus were
used, while in others  10'-  doses were added.  Four mice lightly anesthetized with ether
were inoculated  intranasally  with  each  serum-virus mixture  and were  observed for  11
days.  Deaths  were recorded  daily as they occurred.  All mice  which survived  the ob-
servation period were autopsied, and the extent of pulmonary consolidation was recorded
by the  grading  method previously  described  (19).  Dilutions of single  immune  ferret
serum of known titer against  the PR8 strain were included in each test.
Virus Titrations.-
The virus titration technique  corresponded exactly to that previously  described  (19).
In  the case  of the neutralization  tests, groups  of six  mice  were  inoculated  with  each
decimal  dilution of virus.  To determine  the virus content  of the various vaccines,  how-
ever, only four mice were inoculated with each decimal dilution  of the initial suspension.
The  test mice were  observed for a  period identical with that indicated above,  and the
survivors were  autopsied  in a similar manner.
Calculation  of End Points.-
Both the serum dilution end points and the virus titration end points were calculated
by the 50 per cent end point method of Reed and Muench  (20).  In the neutralization
tests the 50 per cent mortality  end point was used as previously described  (19).  In the
case of titrations of the virus content of the vaccines, both the 50 per cent mortality and
50  per  cent  mouse  pneumonia  end  points  were  determined.  This  latter  end  point
corresponded  to  that  dilution  of virus  which  was  just  capable  of producing  definite
pneumonia  in  50  per cent  of mice.  Definite  influenza  A  virus  pneumonia  was  con-
sidered to be present  when one-fourth or more of the mouse lung showed consolidation.
This dilution was  considered equal to  one 50 per cent mouse pneumonia dose of virus,
and it will be termed hereafter M.P.D.
Calculation of Neutralizing Capacity of Serum.-
The neutralizing  capacity of a serum was  calculated  from  its neutralizing  titer and
the quantity of virus used in the neutralization test in the manner described previously
(21).  The  neutralizing  capacity  of  a serum  is  the  maximum  number  of 50  per cent
mortality doses of influenza A virus which can be neutralized by 0.05  cc. of the serum.
With the great majority of human sera this number is large, and consequently it is con-
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venient  to express  the neutralizing  capacity  logarithmically.  The advantages  of using
neutralizing  capacities  instead  of  serum  titers  have  been  discussed  already  (21).
Throughout  the remainder  of this paper neutralizing capacity will frequently be referred
to merely as  N.C.
EXPERIMENTAL
For the purposes  of  testing  the  antigenicity  of  various vaccines,  volun-
teers were chosen at random.  No effort was made to select individuals on
the basis that their serum  had a particular  neutralizing  capacity.  A pre-
liminary  serum  specimen  was  obtained  from each  volunteer  immediately
before  vaccination,  and  additional  serum  was  taken  at varying  intervals
after  vaccination.  The  neutralizing  capacities  of  these  sera  against  the
PR8 strain of influenza  A virus were determined  as described above.  In a
previous report it has been demonstrated  (22) that the standard neutralizing
antibody  titers  of  the  sera of  a large  number  of  individuals  studied  for  a
period  of  2  years,  although  they  remained  relatively  constant  for  each
individual  during  this  period,  showed  marked  differences  from one  indi-
vidual to another.  However, it was found that approximately  97 per cent
of normal individuals possessed  sera which  fell into one or the other of  the
first  three  standard  neutralizing  titer  groups.  These  titer  groups  were:
(a) less  than  1:4,  (b)  1:4 to  1:15,  and  (c) 1:16  to  1:64.  To  facilitate  a
correlation between what has previously been published (15,  21)  concerning
standard neutralizing antibody titers and the interpretation of the effective-
ness of various types of vaccines containing  influenza A virus, neutralizing
capacity  ranges  were  chosen  which corresponded  quite  closely to the three
titer groups  mentioned.  Volunteers  were  arranged  in order  of  increasing
neutralizing  capacity  of  their  prevaccination  serum,  and  those  in  each
neutralizing  capacity  range  were  considered  as  a  group.  In  the  various
tables  which are  to  be presented  the neutralizing  capacity  range log  2.50
to 4.35 would include only those persons whose prevaccination  sera possessed
a  so  called  standard  titer  of  <1:4.  The  neutralizing  capacity  range  log
4.36 to 5.22 would include only those individuals whose prevaccination  sera
had a standard  neutralizing  titer of  1:4 to  <1:16, while  the neutralizing
capacity  range log 5.23  to 6.09  would contain  only those volunteers  whose
prevaccination  sera  had  a  standard  neutralizing  titer  of  1:16  to  <1: 64.
Results of Human Vaccination.-
Vaccine  No.  .--Each of  the  ten human volunteers  was  given a  single
subcutaneous  injection  of  2  cc.  of  tissue  culture  vaccine  No.  1.  This
quantity  of  vaccine  contained  10 - .8 fifty  per  cent  M.P.D.  of  fully  active
influenza  A virus.  Serum was obtained  from each individual immediately
before vaccination,  as well as  1 and  2 weeks thereafter.  The neutralizing
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capacities of these sera were determined against the PR8 strain of influenza
A  virus  in  the  manner  described  above.  The  results  of  these  tests  are
shown in Table I.  It  will  be seen that almost  no increase in neutralizing
capacity  (N.c.)  occurred  during  the  1st  week  after  vaccination  and  that
TABLE  I
Vaccine No. 1. Neutralizing Capacities of Sera of Human Beings before and after Administration
of Tissue Culture Vaccine Containing  Active Influenza A  Virus
Neutralizing capacity  of serum log  Increase in N.C. log
Volunteers  Postvaccination  Postvaccination
Range  Prevaccination
wk.  2wks.  wk.  2 wks.
1  2.50  3.93  4.94  4.94  1.01  1.01
8  to  3.93  3.93  4.36  0.00  0.43
4.35
Mean ...............  3.93  4.43  4.65  0.50  0.72
3X  5X
4  4.36  4.36  4.94  0.00  0.58
2  4.62  4.94  4.94  0.32  0.32
9  4.36  4.62  4.80  5.51  0.18  0.89
6  to  4.80  4.80  5.67  0.00  0.87
10  5.22  4.80  4.80  4.80  0.00  0.00
3  4.94  4.94  5.23  0.00  0.29
5  4.94  4.94  5.67  0.00  0.73
Mean ...............  4.72  4.79  5.25  0.07  0.53
0X  3X
7  5.23  5.67  5.67  5.67  0.00  0.00
to
6.09
Mean ...............  5.67  5.67  5.67  0.00  0.00
OX  OX
* One subcutaneous injection  containing  10"68 fifty per cent  M.P.D.  of influenza  A virus was
given each  individual.
even  in  the  low  N.C.  range  a  mean  increase  of  but  fivefold  occurred  in
2 weeks.  In the mid N.c.  range the mean  increase  2 weeks after vaccina-
tion was but threefold.
Vaccine No. 2.-Each  of ten human volunteers  was given a single sub-
cutaneous  injection  of  2  cc.  of mouse  lung  vaccine  No.  2.  This  vaccine
had been inactivated  by the addition  of formaldehyde,  as described  above.
The quantity injected represented  10'.4fifty per cent M.P.D.  of influenza  A
virus before inactivation.  Serum was obtained from each individual imme-
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diately before vaccination, as well as 1 and 2 weeks thereafter.  Serum was
also  obtained  from  some  volunteers  17  weeks  after  vaccination.  The
neutralizing  capacities of  these  sera  against the  PR8 strain  of  influenza  A
virus  were  determined  as  described  above.  The  results  are  shown  in
Table  II.  It  will  be noted  that  a definite  increase  in  mean  neutralizing
TABLE II
Vaccine No. 2.  Neutralizing Capacities  of Sera of Human Beings before and after Administration
of Mouse Lung Vaccine Containing  Inactivated Influenza A  Virus
Volunteer*
Range
1  2.50
4  to
7  4.35
Mean ..........
2  4.36
to
n10  5.22
5
Mean ..........
6  5.23
8  to
9  6.09
Mean ...........
I  Neutralizing  capacity of  serum log
Prevac-
cination
3.93
3.93
3.93
3.93
4.62
4.80
4.80
4.94
4.81
5.67
5.67
5.67
5.67
Postvaccination
1  wk.
4.94
4.80
3.93
4.55
5.51
5.67
6.53
5.23
5.75
5.67
5.80
5.67
5.71
2 wks.
5.51
4.80
3.93
4.75
6.53
6.53
6.53
5.80
6.37
5.67
5.67
6.53
5.95
17 wks.
4.94
4.94
3.93
4.60
5.46
5.67
6.53
5.80
5.86
Increase in N.c.  log
Postvaccination
1  wk.
1.01
0.87
0.00
0.62
4X
0.89
0.87
1.73
0.29
0.94
9X
0.00
0.13
0.00
0.04
OX
2 wks.
1.58
0.87
0.00
0.82
7X
1.91
1.73
1.73
0.86
1.56
36X
0.00
0.00
0.86
0.28
2X
17 wks.
1.01
1.01
0.00
0.67
5X
0.84
0.87
1.73
0.86
1.07
12X
* One subcutaneous  injection which contained, before  inactivation,  10
9.4 fifty  per cent x.P.D.
of influenza  A virus  was given  each  individual.
capacities  had occurred  in  both the low  and  mid  N.C.  ranges  during  the
1st  week.  This  increase  was  considerably  more  definite  at  the  end  of
2 weeks,  at  which  time  the  mean  increase  in  N.C.  in  the  low  range  was
sevenfold,  while  in the mid  N.C.  range it was  36  times.  In  the high  N.C.
range,  however, the mean increase during the same period was but twofold.
17  weeks after vaccination  the mean increase  in  N.C.  in the low range  was
fivefold, whereas in the mid N.C.  range it had dropped to  12 times.
Vaccine No. 3.-Each of  ten human  volunteers was  given a single injec-
tion of  2 cc. of ferret lung and spleen vaccine No. 3 subcutaneously.  This
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vaccine had been inactivated by the addition of formaldehyde in the manner
described  above.  The  quantity  injected  contained,  before  inactivation,
105'  fifty per  cent M.P.D.  of influenza  A virus.  Serum was obtained  from
each individual immediately  before vaccination,  as well as  1 and  2 weeks
TABLE  III
Vaccine No.  3.  Neutralizing Capacities of Sera of Human Beings before and after Administration
of Ferret  Lung and Spleen Vaccine Containing  Inactivated Influenza A  Virus
Neutralizing capacity of serum log  Increase in N.c.  log
Volunteer*  Postvaccination  Postvaccination
Range  Prevaccination
I wk.  2 wks.  1 wk.  2 ws.
1  2.50  3.93  4.36  4.94  0.43  1.01
to
4.35
Mean  ...............  3.93  4.36  4.94  0.43  1.01
3.  X  10X
9  4.36  4.62  4.80  0.26  0.46
4  4.62  4.80  '  5.23  0.18  0.61
5  4.62  4.36  5.67  -0.26  1.05
8  4.36  4.62  4.80  5.80  0.18  1.18
2  5.22  4.80  4.80  5.67  0.00  0.87
3  4.94  4.80  5.80  -0.14  0.86
6  4.94  5.67  5.80  0.73  0.86
10  4.94  5.23  5.67  0.29  0.73
Mean...............  4.73  4.93  5.55  0.20  0.82
OX  7X
7  5.23  5.23  5.51  5.23  0.28  0.00
to
6.09
Mean ..............  5.23  5.51  5.23  0.28  0.00
2X  OX
*  One subcutaneous  injection which  contained,  before inactivation,  10
5 6
a fifty per cent  M.P.D.
of influenza  A virus  was given each  individual.
thereafter.  The  neutralizing  capacities  of  these  sera  were  determined
against  the  PR8  strain  of  influenza  A  virus.  The  results  are  shown  in
Table  III.  It is  evident  that  little or  no  increase  in  mean  neutralizing
capacity had occurred  during the  1st week.  At the end of  the 2nd week,
however,  the single  individual in  the low  N.C.  range showed an increase  of
tenfold,  whereas  those  in  the  mid  N.C.  range  had  a  mean  increase  of
sevenfold.
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Vaccine No. 4.-Each of nine human volunteers was given a single injec-
tion of 2 cc. of complex ferret lung and spleen vaccine No. 4 subcutaneously.
This vaccine  had been inactivated  by the addition  of formaldehyde  in the
manner  described  above.  Before  inactivation  the quantity  injected  con-
TABLE  IV
Vaccine No. 4.  Neutralizing Capacities of Sera of Human Beings before and after Administration
of Complex Ferret Lung and Spleen Vaccine Containing  Both Inactivated
Influenza A  Virus and Canine Distemper Virus
Volunteer  I
Range
10  2.50
to
4.35
Mean ...........
9
7
1  4.36
3  to
4  5.22
6
2
Mean ...........
5  5.23
to
6.09
Mean ...........
Neutralizing capacity  of serum log
cination
3.93
3.93
4.62
4.62
4.80
4.80
4.80
4.94
5.05
4.80
5.23
5.23
Postvaccination
2 wks.
4.80
4.80
5.67
5.67
5.51
5.23
5.67
5.67
5.51
5.56
5.51
5.51
4 ws.
5.51
5.23
5.67
5.89
5.89
5.64
5.67
5.67
12 wks.
5.12
5.67
6.28
5.67
5.67
5.68
5.23
5.23
Increase  in x.c.  log
Postvaccination
2 wks.
0.87
0.87
7X
1.05
1.05
0.71
0.43
0.87
0.73
0.46
0.76
6X
0.28
0.28
4 wks.
0.89
0.43
0.87
0.95
0.84
0.79
6X
0.44
0.44
2X  I  3X
12 wks.
0.50
0.87
1.48
0.87
0.62
0.87
7X
0.00
0.00
OX
* One subcutaneous injection which contained,  before inactivation,  106.1  fifty per cent M.P.D.
of influenza  A  virus  was  given  each  individual.
tained  10 .1 fifty per cent M.P.D. of influenza A virus.  Serum was obtained
immediately before vaccination from each individual, and 2, 4, and 12 weeks
after vaccination  from as many volunteers  as possible.  The  capacities  of
these  sera  to neutralize  the PR8  strain  were  determined,  and  the results
are  shown in Table IV.  2 weeks after vaccination the single individual in
the low  N.C.  range  showed  an increase  of  sevenfold,  whereas  those in the
mid N.C.  range  had a mean  increase  of  sixfold.  It is obvious  that  theseF.  L.  HORSFALL,  JR.,  E.  H.  LENNETTE,  AND  E.  R.  RICKARD
increases  in specific  neutralizing antibodies were  almost identical in magni-
tude to those presented in Table III.  However, it is also evident from the
results shown  in Table IV that during the first 3 months following  vaccina-
tion  there was  no  significant  reduction  in the  increased  antibody levels.
It will  be recalled  that ferret lung and spleen  vaccine  No.  3  contained only
TABLE  V
Vaccine No.  5.  Neutralizing Capacities of Sera of Human Beings before and after Administration
of Complex Ferret Lung and Spleen Vaccine Prepared  with Y Strain
of Canine  Distemper Virus
Neutralizing capacity of serum log  Increase in N.C.  log
Volunteer*  Postvaccination  Postvaccination
Range  Prevaccination
2 wks.  4 wks.  2 wks.  4 wks.
9  2.50  3.93  3.93  3.93  0.00  0.00
10  to  3.93  3.93  3.93  0.00  0.00
4.35
Mean..............  3.93  3.93  3.93  0.00  0.00
OX  OX
1  4.62  4.80  4.94  0.18  0.32
5  4.62  4.36  4.62  -0.26  0.00
7  4.36  4.62  3.93  3.93  -0.69  -0.69
3  to  4.80  4.80  4.80  0.00  0.00
2  5.22  4.80  4.80  4.62  0.00  -0.18
8  4.80  4.94  4.94  0.14  0.14
6  4.80  4.80  - 0.00  -
Mean..............  4.72  4.64  4.64  -0.08  -0.07
OX  OX
10  5.23  5.67  5.67  5.51  0.00  -0.16
to
6.09
Mean  .............  5.67  5.67  5.51  0.00  -0.16
OX  OX
*  One  subcutaneous  injection  of this vaccine  was given  each  individual.
inactivated  influenza A virus, whereas  complex  ferret lung and spleen vac-
cine No.  4 contained  both  inactivated  influenza  A virus and  the X strain
of canine  distemper  virus.
Vaccine No. 5.-Each of ten human  volunteers  was  given  a  single sub-
cutaneous injection of 2 cc. of complex ferret lung and spleen vaccine No. 5
subcutaneously.  This vaccine  was prepared  with  the Y  strain  of canine
distemper virus.  Even before inactivation with formaldehyde  this vaccine
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contained  no demonstrable  active influenza  A virus, as was to be expected
from  the  results  of  experiments  previously  reported  (10).  Serum  was
obtained immediately before vaccination  from each individual and from all
but one volunteer  2 and 4 weeks after vaccination.  The capacities of these
sera to neutralize the PR8 strain were determined, and the results are pre-
sented  in  Table  V.  No  increase  in mean  neutralizing  capacity  occurred
in any of the three N.c.  ranges at either 2 or 4 weeks following  the adminis-
tration  of  this  vaccine.  In  fact,  the  neutralizing  capacities  of  the  three
sera from each of  the individuals were found to be almost identical.
Vaccine No. 6.-Each of  five human  volunteers  was given  a  single  sub-
cutaneous  injection of 2 cc.  of  chick embryo  vaccine  No.  6.  This vaccine
contained  fully  active  influenza  A  virus  which  had  not been  adapted  to
mice.  The  titer of the virus  as determined  in this  species  was, therefore,
meaningless.  Serum  was  obtained  immediately  before,  as  well  as  2,  4,
and 21 weeks after vaccination from as many individuals as possible.  The
capacities  of  these  sera  to  neutralize  the PR8  strain of  influenza  A  virus
were determined.  The results are presented in Table VI.  The single indi-
vidual in the low N.C.  range  showed  an increase  of sevenfold, both at 2 and
4  weeks  after vaccination.  The  three  individuals  in  the  mid  N.C.  range
showed  no  significant  increase  at  2 weeks,  a twofold  increase at  4 weeks,
and a threefold  increase at 21  weeks.
Vaccine No. 7.-Each of  five human  volunteers  was given  a single  sub-
cutaneous injection of  1 cc. of  complex chick embryo vaccine No. 7.  This
vaccine had been inactivated by the addition of formaldehyde.  The influ-
enza A virus used had not been adapted to mice.  Even before inactivation,
therefore,  its  titer in  this  species  was of  no  significance.  Serum  was  ob-
tained  immediately  before  vaccination,  as  well  as  1, 2,  4,  and  21  weeks
thereafter  from as many individuals  as possible.  The neutralizing  capaci-
ties of  these  sera  against  the PR8  strain of  influenza  A  virus were  deter-
mined.  The results  are presented in Table VII.  1 week after vaccination
the single individual in  the low N.C.  range  showed an increase  of sevenfold,
whereas  those  in the  mid  N.C.  range  showed  an increase  of  twofold.  At
2 weeks  after vaccination  the  increases  in  these  ranges  were  found  to be
55  times and  10  times, respectively.  4 weeks  after vaccination  they  were
74  times and  10 times,  respectively,  while at 21 weeks  they were  10  times
and 7 times, respectively.  It is quite evident that the results obtained with
this vaccine were very different from those which are presented in Table VI.
It  will be  recalled  that  chick embryo  vaccine  No.  6 contained  only  influ-
enza A virus which  was fully active  when injected, whereas  complex chick
embryo  vaccine  No.  7 was  prepared  from  embryos  inoculated  with  both
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Vaccine No.  6.  Neutralizing Capacities  of Sera of Human Beings before and after Administration
of Chick Embryo Vaccine Containing  Active Influenza A  Virus
Range
2.50
to
4.35
Mean  ..........
2  4.36
5  to
3  5.22
Mean  ..........
1  5.23
to
6.09
Mean  ..........
Neutralizing capacity of serum log
Prevaccina-
tion
3.93
3.93
4.80
4.80
4.94
4.84
5.23
5.23
Postvaccination
2 wks.
4.80
4.80
5.23
4.94
4.94
5.03
6.10
6.10
4 wks.
4.80
4.80
5.67
4.94
4.80
5.13
5.67
5.67
21 wks.
5.81
5.05
5.05
5.31
5.81
5.81
Increase  in  N.C. log
Postvaccination
2 wks.
0.87
0.87
7X
0.43
0.14
0.00
0.19
OX
0.87
0.87
7x
4 wks.
0.87
0.87
7X
0.87
0.14
-0.14
0.29
2X
0.44
0.44
3X
21 wks.
1.01
0.25
0.09
0.45
3X
0.58
0.58
4X
*  One  subcutaneous injection  was given  each individual.  Since this influenza  A virus had
not been adapted to mice, the exact titer could not be determined in this species.
TABLE  VII
Vaccine No. 7.  Neutralizing Capacities of Sera of Human Beings before and after Administration
of Complex Chick Embryo Vaccine
Volun-
teer*
3
Range
2.50
to
4.35
Mean .........
4  4.36
1  to
2  5.22
5
Mean .........
Neutralizing capacity of serum  log
Postvaccination
I wk.
4.80
4.80
4.36
5.51
5.23
4.80
4.97
2 wks.
5.67
5.67
4.80
5.67
6.53
5.67
5.67
4 wks.
5.80
5.80
4.80
5.67
6.53
5.67
5.67
21 wks.
4.94
4.94
5.05
5.81
5.43
Prevac-
dnation
3.93
3.93
4.36
4.80
4.80
4.80
4.69
Increase  in  N.C. log
Postvaccination
1 wk
0.87
0.87
7X
0.00
0.71
0.43
0.00
0.28
2X
2 wks.
1.74
1.74
55X
0.46
0.87
1.73
0.87
0.98
10X
4 wks.
1.87
1.87
74X
0.46
0.87
1.73
0.87
0.98
10X
Volunteer'
4
21 wks.
1.01
1.01
10ox
0.69
1.01
0.85
7X
*  One subcutaneous injection was given each individual.  Since this influenza A virus had not
been adapted to mice, the exact titer could not be determined  in this species.
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influenza  A virus and  the X strain  of  canine  distemper virus.  Moreover,
the  latter vaccine  was inactivated  by formaldehyde  and might have  been
TABLE  VIII
Vaccine No. 8. Neutralizing Capacities  of Sera of Human Beings before and after Administration
of Chick Embryo Vaccine Containing  Influenza A  Virus
Volunteer
5*
8*
7*
5**
8**
10**
3**
9**
3*
Neutralizing  capacity of serum log
Range
2.50
to
4.35
Mean
4*
6*
9*
4**
4.36
to
5.22
Mean ..............
7**
2** 5.23
1*
2*  to
10*  6.09
1**
Mean ..............
Prevaccination
3.50
3.50
3.93
3.93
3.93
3.93
3.93
3.93
4.18
3.86
4.80
4.80
4,80
4.80
4.80
5.51
5.51
5.67
5.67
5.67
5.80
5.64
Postvaccination
2 wks.
5.05
4.18
4.62
5.05
4.72
5.67
5.67
5.67
5.67
5.67
6.53
5.67
5.95
3 wks.
4.80
4.36
4.18
3.93
3.93
4.94
4.94
4.62
5.05
4.53
5.23
4.80
4.80
5.67
5.12
5.67
5.51
5.67
5.74
5.67
6.37
5.77
Increase  in  N.C. log
Postvaccination
2 wks.
1.55
0.68
0.69
0.87
0.94
9X
0.87
0.87
0.87
0.87
7X
0.00
0.86
0.00
0.28
2X
3 wks.
1.30
0.86
0.25
0.00
0.00
1.01
1.01
0.69
0.87
0.67
5X
0.43
0.00
0.00
0.87
0.32
2X
0.16
0.00
0.00
0.07
0.00
0.57
0.13
OX
*  One subcutaneous  injection  containing  106 a fifty per  cent  M.P.D.  was given.
**  Vaccine  given intramuscularly.
expected to produce a less vigorous rather than a considerably more definite
specific  neutralizing  antibody  response.  It  seems  of  considerable  interest
that the increased neutralizing  capacities which followed the administration
of this vaccine declined but little during the first 5 months.
Vaccine No. 8.-Each  of  nineteen human  volunteers  was  given  a  single
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injection  of 1 cc. of  chick embryo vaccine  No. 8.  Ten volunteers received
the vaccine subcutaneously  while nine  were given intramuscular  injections.
This quantity of vaccine  contained  106.3  fifty per cent M.P.D.  of influenza  A
virus which was fully active when administered.  Serum was obtained from
each  individual  immediately  before  vaccination  and  3  weeks  afterwards.
From  those persons  who  received  the  vaccine  subcutaneously  serum  was
also obtained  2 weeks  after vaccination.  The  capacities  of these  sera to
neutralize  the  PR8  strain  were  determined,  and  the results  are  shown  in
Table  VIII.  It will  be  noted  that  the  four  individuals  in  the  low  N.C.
range had a mean  increase  of ninefold at 2 weeks, whereas at 3 weeks the
total group in this range showed a mean increase  in N.c.  of  fivefold.  The
individuals  in  the mid  N.C.  range  showed  an increase at 2 and  3  weeks  of
sevenfold and twofold, respectively.
Vaccine  No.  9.-Each of  twenty-four  human  volunteers  was  given  a
single  injection of  1 cc.  of  complex  chick embryo  vaccine  No.  9  subcuta-
neously.  This  vaccine  was  inactivated  by  the addition  of  formaldehyde
and  had  been  desiccated  in  the  frozen  state.  Before  inactivation  the
quantity  of vaccine  injected  contained  106.9  fifty per  cent  M.P.D.  of  influ-
enza A virus.  Serum was obtained from each individual immediately before
vaccination  and  from as many as possible 2 and 4 weeks  thereafter.  The
capacities  of  these sera to neutralize the  PR8 strain were determined,  and
the  results  are  presented  in  Table  IX.  It will  be  seen  that  those  indi-
viduals in the low N.c.  range whose sera were studied 2 weeks after vaccina-
tion  showed a mean  increase  of  79  times,  whereas  those  whose  sera  were
obtained 4 weeks  after vaccination  had a mean increase  of 31  times.  The
seven  volunteers  in  the  low  N.C.  range  from  each  of  whom  serum  was
obtained  2 and  4 weeks  after vaccination  showed  a mean  increase  in N.C.
at  these  intervals  of  68  times  and  58  times,  respectively.  Those  indi-
viduals in the mid N.C.  range whose  sera were examined 2 weeks after vac-
cination  showed  a  mean  increase  of  15  times,  while  the  larger  number
whose sera were obtained at 4 weeks had a mean increase of 9 times.  From
five  volunteers  in  the mid  N.C.  range  serum  was  obtained  both  at 2 and
4  weeks  after  vaccination.  In  this  group  the  mean  increase  in  N.C.  at
these periods was 12  times and 9 times, respectively.
It  is apparent  that these results are  very different  from those presented
in Table VIII and that the increases in neutralizing capacity which followed
the administration  of the complex vaccine  were  considerably greater  than
those which followed  the administration of a comparable vaccine containing
influenza  A  virus  alone.  It  will  be  recalled  that  chick  embryo  vaccine
No.  8  contained  only  fully active  influenza  A  virus,  while  complex  chick
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TABLE  IX
Vaccine No. 9.  Neutralizing Capacities of Sera of Human Beings before and after Administration
of Complex Chick Embryo Vaccine
Neutralizing  capacity of serum log
Volunteer*
Range
11
1
10
24
7  2.50
9  to
4  4.35
8
15
16
23
Mean  ..............
14
19
6
17
20
21
25
12
22
3
13
4.36
to
5.22
Mean.
2
18
5.23
to
6.09
Mean  ..............
Prevaccination
2.50
3.36
3.50
3.50
4.05
4.05
4.23
4.23
4.23
4.23
4.23
3.83
4.37
4.37
4.67
4.67
4.80
4.90
4.90
4.96
5.10
5.10
5.10
4.81
5.53
5.96
5.74
Postvaccination
2 wks.
5.10
6.40
6.68
5.10
5.32
4.96
6.11
5.10
6.68
5.72
5.96
4.96
5.10
6.40
6.68
6.83
5.96
5.82
6.40
6.00
4 wks.
4.96
6.11
4.13
5.53
5.20
5.53
5.10
6.68
4.67
5.32
5.10
6.11
5.11
5.96
5.96
5.96
5.96
6.83
4.96
5.53
5.66
6.40
6.40
Increase in N.C.  log
Postvaccination
2 wks.
2.60
3.04
3.18
1.05
1.27
0.73
1.88
0.87
2.45
1.90
79X
1.59
0.29
0.43
1.44
1.58
1.73
1.18
15X
0.29
0.44
0.36
2X
4 wkis.
2.46
2.75
0.63
1.48
0.97
1.30
0.87
2.45
0.44
1.48
31X
0.73
1.74
0.44
1.29
1.16
1.06
1.06
1.87
-0.14
0.43
0.96
9X
0.44
0.44
3X
* One subcutaneous  injection  containing,  before  inactivation,  106-9  fifty  per  cent M.P.D.  of
influenza  A virus was  given  each  individual.
embryo  vaccine  No.  9  was  prepared  from  embryos  inoculated  with  both
influenza  A virus and  the X strain  of canine  distemper virus.  Moreover,
the latter vaccine was inactivated by the addition of formaldehyde.  It  was
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to  be  expected  that  the  active  simple  vaccine  might  produce  a  greater
specific  antibody  response  than  the  inactive  complex  vaccine,  whereas
quite the reverse was found to be the case.
A summary analysis of the mean increases in neutralizing capacities which
occurred  2  weeks  after  the  administration  of  each  of  the  nine  vaccines
studied is presented in Table X.  The mean antibody increases  observed in
each of the three N.C. ranges, as well as that which was observed irrespective
of range, are shown.  It is apparent that the greatest increase in neutralizing
capacity  followed  the  injection  of  complex  chick  embryo  vaccine  No.  9
and  that  the  next  most marked  increase  occurred  after  the  injection  of
TABLE  X
Mean Increase in  Neutralizing Capacities  of Human Sera 2 Weeks after Administration of
Various Vaccines Containing  Influenza A  Virus
Vaccine
No.  Source  Type
1  t.c.  Influenza alone
2  m.l.  c 
3  f.l.s.
4  f.l.s.  Complex X
5  f.l.s.  Complex Y
6  ch.em.  Influenza alone
7  ch.em.  Complex X
8  ch.em.  Influenza alone
9  ch.em.  Complex X
Mean  neutralizing capacity increase
Log N.C.  range'  All  ranges
2.50  4.36  5.23
to  to  to  Log  Arith.
4.35  5.22  6.09
0.72  0.53  0.00  0.52  3.2X
0.82  1.56  0.28  0.95  9.OX
1.01  0.82  0.00  0.76  5.7X
0.87  0.76  0.28  0.72  5.2X
0.00  -0.08  0.00  -0.06  O.OX
0.87  0.19  0.87  0.46  2.9X
1.74  0.98  - 1.13  13.5X
0.94  0.87  0.28  0.77  5.9X
1.90  1.18  0.36  1.47  29.2X
complex chick embryo  vaccine No.  7.  It should again  be noted that vac-
cine No. 5, which was prepared with the Y strain  of canine distemper virus,
produced  no increase  whatever  in  antibody  levels.
DISCUSSION
Since normal experimental  animals do not possess  circulating  antibodies
against influenza A virus,  evidence  concerning the effectiveness  of vaccines
containing this virus obtained in these species may not be directly applicable
to man.  The fact that the great majority of normal human  beings possess
considerable  quantities  of specific  neutralizing  antibodies against  influenza
A virus makes it difficult  to assess  the efficacy  of a vaccine containing  this
virus  in man.  Inasmuch  as  certain  normal individuals  may possess  very
different  amounts  of  neutralizing  antibodies,  in  some  cases  as  much  as
I  I
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10,000  times  more  than in  others,  it is essential  that  individual  antibody
levels  be determinedexactly  if accurate  data are tobe obtained  concerning
the  production  of  antibodies  which  results  from  the  administration  of  a
given vaccine.
During  the  course  of  the  present  studies  it  became  apparent  that  the
quantitative  increase  in  circulating  antibodies  which  followed  the  sub-
cutaneous injection of a particular vaccine was dependent to a considerable
extent upon  the initial  quantity of  antibodies possessed  by  a given  indi-
vidual.  In general, the lower the prevaccination antibody level, the greater
was the postvaccination production of antibodies.  Because of this observa-
tion it has  seemed desirable  to group  individuals with certain  initial anti-
body levels  so  that a reasonable  comparison  could  be made  between  the
antibody  responses  produced  in  comparable  groups  by  different  vaccines.
However,  the degree  of  difference  in  specific  antigenicity  which  was  pos-
sessed  by  the  complex  chick  embryo  vaccines  as  opposed  to  the  others
tested was sufficiently  great to be reflected  even in  the results obtained in
the whole groups  irrespective of  their initial antibody levels.
Under the conditions of these experiments it was found that the parenteral
administration  of fully active  tissue culture virus or chick embryo virus in
man  was  followed  by  a  definite,  though  not very marked,  production  of
specific  neutralizing  antibodies.  The  increases  in  antibody  levels  which
were observed after the injection of active tissue culture virus were probably
somewhat  less  than those  previously  reported by Francis  and  Magill  (4).
However, it should  be pointed out that these workers  gave multiple injec-
tions of the virus, whereas in the present study only one injection was made.
It  seems  worthy  of  note  that no  particularly  striking  differences  in anti-
genicity for man  were encountered with either  the active tissue  culture  or
the active  chick embryo viruses  even  though three  distinct passage  series
of  the original PR8  strain were  used.  These three series  for more  than 4
years have been maintained in very  different biological  environments;  viz.,
tissue culture, ferret lung, and mouse lung.
The inactivated mouse lung virus in man was found to stimulate the pro-
duction of a  considerably  greater quantity  of  neutralizing  antibodies  than
did the inactivated ferret lung virus.  It may be that this difference in anti-
genicity is related to similar differences  observed in mice with related vac-
cines  by  Andrewes  and  Smith  (23).  However,  it  seems  more  reasonable
in the present  circumstances  to explain  the different  antigenicity  of  these
preparations  on the  basis  of  their  very  obviously  different virus  content.
The mouse titration results indicated that the mouse lung vaccine contained
over  10,000 times more virus than the ferret lung and spleen vaccine.  In
fact, the mouse lung vaccine contained some 300 times more virus than any
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other  vaccine  studied.  The  increases  in  antibody  levels  which  were
observed  after the injection  of inactivated  mouse lung virus appear  to be
of approximately the same order of magnitude as those which were obtained
previously  with  similar  preparations  by  Smith,  Andrewes,  and  Stuart-
Harris  (7) and  by Taylor and Dreguss  (8).  However,  it should  be noted
that a considerable  decrease  in  these  raised antibody levels  had  occurred
after 4  months.
The complex ferret lung and spleen vaccine  containing inactivated  influ-
enza A virus and the X strain of canine distemper virus was found to be no
more antigenic in man than the comparable  ferret vaccine which contained
only influenza  A virus.  This vaccine was prepared  in a manner  as nearly
as possible identical with the complex ferret vaccine previously described (9).
Moreover, it was tested subcutaneously  in ferrets and was found to stimu-
late the production  of antibodies in  10 days in this species equal to a mean
neutralizing  capacity of log 4.94.  Furthermore,  it resulted  in the produc-
tion  in ferrets  of  definite  immunity  to  the intranasal  inoculation  of  1000
infectious doses of either the PR8 or the W.S.  strain.
The complex ferret  lung and  spleen  vaccine  prepared with the Y strain
of canine  distemper  virus failed  to  stimulate  the production  of any addi-
tional  antibodies  against  influenza  A virus.  It was  stated previously  (9)
that this strain, recently  isolated  from the spleen  of  an  infected  dog,  was
ineffective  when  used  in  the  preparation  of  a  complex  vaccine.  It  was
shown  also  (10)  that  the X  strain,  although  possessing  no  demonstrable
antigenic  differences  from the Y strain,  markedly altered  the usual course
of influenza  virus infection in the ferret,  whereas the Y strain did not.  It
seems reasonable to suggest that the X strain possesses certain peculiarities
which may not be common to other strains of canine  distemper virus.
The  complex  chick  embryo  vaccines,  although  containing  inactivated
virus,  caused  a  definitely  greater  production  of  neutralizing  antibodies
than  did  comparable  vaccines  prepared  from embryos  infected  only with
influenza  A  virus,  even  though  the latter vaccines  contained  active virus.
In fact, vaccine  No.  9 stimulated  the formation of more specific antibodies
than any other vaccine tested.  In individuals with comparable prevaccina-
tion antibody levels vaccine No. 7 appears to have been equally as effective
an antigen as vaccine No. 9, although the number of individuals tested with
the former vaccine is probably too small to permit of accurate comparison.
It  may  again  be  worth  noting  that  different  passage  series  of  the  PR8
strain, i.e., ferret lung and mouse lung viruses which  had both been estab-
lished  in  the  chick  embryo,  were  used  in  the  production  of  these  two
complex vaccines.
Following the injection of either  complex ferret lung  and spleen or corn
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plex chick embryo vaccines prepared  with the X strain  of canine distemper
virus,  the  increased  antibody  levels  against  influenza  A  virus  remained
relatively  unaltered  for a period of  at least  12 weeks  and 21 weeks,  respec-
tively.  It  was  shown  in  a  previous  paper  (24)  that  after  an  attack  of
influenza  A  striking  reductions  in  the  initially  increased  antibody  levels
occurred  during similar periods.  Despite  the  fact that the mean increases
in  neutralizing  antibodies  which  occurred  in  the  first  2 weeks  after  the
onset of influenza  A were more marked than those which followed the injec-
tion  of  complex  vaccines,  the  residual  antibody  levels  in  comparable
neutralizing  capacity  groups,  approximately  12  and  21  weeks  after  an
attack of  influenza  A or  the  administration  of  a  complex vaccine,  appear
to have been  of  the same  order of  magnitude.  If,  as seems  not unlikely,
neutralizing  antibody levels  actually reflect  relative  immunity  to infection
by influenza  A virus  (22),  it seems possible that the administration  of the
complex  chick embryo  vaccine  may  have resulted  in  the production  of  a
degree of immunity at least as satisfactory and as persistent as that which
followed  the  disease  itself.  Field  tests  under  natural  conditions  in  large
groups  of  vaccinated  and  unvaccinated  individuals  exposed  to  epidemics
of  proven  influenza  A  will  obviously  be  necessary  before  the  possible
prophylactic  effectiveness  of  the  complex  chick  embryo  vaccine  can  be
definitely  determined.
The actual biological phenomena which  cause the complex  chick embryo
vaccine to be more  effective  in stimulating  the production  of specific  neu-
tralizing  antibodies  against  influenza  A  virus  than  a  similar  vaccine  pre-
pared with influenza  A virus alone remain obscure.  It has previously  been
shown  (10)  that  no  demonstrable  antigenic  relationship  existed  between
influenza A virus and the X strain of canine distemper virus.  Nonetheless,
from the  results presented  herein it seems  evident  that the inoculation  of
chick embryos with a mixture of both influenza  A virus and this particular
strain  of  distemper  virus  leads  to  the  production  of  preparations  more
antigenic  for  man  than  would  have  been  anticipated  on  the  basis  of  the
concentration  of  influenza  A  virus  in  them  as  determined  by  titrations
in mice.  Whether this  result is due  to as yet unmeasured  quantitative or
qualitative  modifications  in  either virus  or in both  is not clearly  evident,
and to enumerate  the various  theoretical possibilities  seems pointless.
CONCLUSION
A quantitative  study of  the  antigenicity  of  various  vaccines  containing
influenza  A  virus  has been  made  in human  beings.  A  complex  vaccine
prepared  from chick  embryos inoculated  with both  influenza  A  virus and
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the X strain of canine  distemper virus was found to be more effective  than
other  vaccines  in  stimulating  the  production  of  neutralizing  antibodies
against  the  former  virus.  The  increased  antibody  levels  which  resulted
from the  administration  of  this  vaccine  remained  almost  unaltered  for at
least 5 months.
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